VitaNova Life Sciences (VNOV) Common Equity (2017 - 2026)

VitaNova Life Sciences has disclosed Common Equity across 10 years of filings, most recently posting $1.9 million for Q3 2026.

• Common Equity for Q3 2026 came in at $1.9 million, up 3.51% year-over-year; the trailing twelve-month figure through Jul 2026 was $1.9 million (up 3.51% YoY), and the FY2026 annual result was $2.1 million, up 7.44% from the prior year.
• Common Equity for Q3 2026 stood at $1.9 million, down from $2.1 million in the prior quarter.
• Across five years, Common Equity topped out at $2.1 million in Q2 2026 and bottomed at -$92217.0 in Q4 2023.
• Average Common Equity over 5 years is $851419.6, with a median of $1.0 million recorded in 2024.
• The widest annual swing landed in 2023, when Common Equity slumped 570.21%; it then surged 1883.23% in 2024.
• Year by year, Common Equity stood at -$30253.0 in 2022, then tumbled by 204.82% to -$92217.0 in 2023, then surged by 1222.22% to $1.0 million in 2024, then jumped by 83.42% to $1.9 million in 2025, then climbed by 1.55% to $1.9 million in 2026.
• The last three Common Equity figures came in at $1.9 million (Q3 2026), $2.1 million (Q2 2026), and $1.9 million (Q1 2026), per Business Quant data.